724423-94-3Relevant academic research and scientific papers
Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535
Duplantier, Allen J.,Dombroski, Mark A.,Subramanyam, Chakrapani,Beaulieu, Aimee M.,Chang, Shang-Poa,Gabel, Christopher A.,Jordan, Crystal,Kalgutkar, Amit S.,Kraus, Kenneth G.,Labasi, Jeff M.,Mussari, Christopher,Perregaux, David G.,Shepard, Rick,Taylor, Timothy J.,Trevena, Kristen A.,Whitney-Pickett, Carrie,Yoon, Kwansik
, p. 3708 - 3711 (2011/07/31)
High throughput screening (HTS) of our compound file provided an attractive lead compound with modest P2X7 receptor antagonist potency and high selectivity against a panel of receptors and channels, but also with high human plasma protein bindi
Combination therapies utilizing benzamide inhibitors of the P2X7 receptor
-
Page/Page column 27, (2010/02/15)
This invention provides methods of treatment of IL-1 mediated diseases comprising administering a pharmaceutically effective amount of a pharmaceutical agent selected from the group of sulfasalazine, a statin, a glucocorticoid agent, an inhibitor of p38 k
